IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

COLELLA, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.351
AS - Asia 1.075
EU - Europa 1.044
SA - Sud America 96
AF - Africa 30
OC - Oceania 4
Totale 3.600
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.304
CN - Cina 329
GB - Regno Unito 306
SG - Singapore 291
IT - Italia 191
DE - Germania 123
BD - Bangladesh 113
SE - Svezia 104
VN - Vietnam 98
HK - Hong Kong 89
BR - Brasile 74
FI - Finlandia 68
RU - Federazione Russa 65
FR - Francia 47
IN - India 44
NL - Olanda 42
CA - Canada 33
IE - Irlanda 28
ID - Indonesia 25
TR - Turchia 17
UA - Ucraina 17
JP - Giappone 12
BE - Belgio 11
KR - Corea 10
MX - Messico 10
ES - Italia 9
ZA - Sudafrica 9
CI - Costa d'Avorio 8
IQ - Iraq 8
DK - Danimarca 7
UZ - Uzbekistan 6
AR - Argentina 5
MA - Marocco 5
PK - Pakistan 5
AT - Austria 4
AU - Australia 4
PH - Filippine 4
PL - Polonia 4
AZ - Azerbaigian 3
CH - Svizzera 3
CL - Cile 3
GR - Grecia 3
KE - Kenya 3
PE - Perù 3
SM - San Marino 3
TH - Thailandia 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
BO - Bolivia 2
CO - Colombia 2
EC - Ecuador 2
EG - Egitto 2
ET - Etiopia 2
EU - Europa 2
LK - Sri Lanka 2
NO - Norvegia 2
NP - Nepal 2
OM - Oman 2
AM - Armenia 1
AW - Aruba 1
BH - Bahrain 1
BN - Brunei Darussalam 1
DO - Repubblica Dominicana 1
EE - Estonia 1
IL - Israele 1
JM - Giamaica 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
ME - Montenegro 1
MT - Malta 1
MY - Malesia 1
NG - Nigeria 1
PT - Portogallo 1
PY - Paraguay 1
RO - Romania 1
SA - Arabia Saudita 1
SI - Slovenia 1
SV - El Salvador 1
TW - Taiwan 1
VE - Venezuela 1
Totale 3.602
Salva come PNG Salva come JPEG
Città #
Southend 277
Ashburn 172
Singapore 168
Chandler 126
Hong Kong 81
Fairfield 71
San Jose 64
Beijing 60
Seattle 53
Helsinki 52
Los Angeles 52
Milan 50
Wilmington 48
Ann Arbor 43
Council Bluffs 39
Dallas 36
Houston 36
Princeton 36
Santa Clara 36
Woodbridge 31
New York 29
Dublin 27
Toronto 27
Cambridge 24
Ho Chi Minh City 24
Buffalo 21
Boardman 20
Dearborn 20
Des Moines 17
Hanover 17
Lauterbourg 16
Hanoi 15
Kiez 15
Frankfurt am Main 14
Jakarta 14
Margão 14
Mountain View 13
Munich 13
Dong Ket 12
Rome 12
Brussels 11
Nanjing 11
Shanghai 11
Bengaluru 10
Phoenix 10
Istanbul 9
The Dalles 9
Abidjan 8
Cangzhou 8
Columbus 8
Fremont 8
Guangzhou 8
Jinan 8
Redmond 8
Shenzhen 8
Chicago 7
Da Nang 7
Fuzhou 7
Moscow 7
Shenyang 7
Tokyo 7
Turin 7
Wanghailou 7
Atlanta 6
Mumbai 6
Nuremberg 6
Turku 6
Cagliari 5
Central District 5
Haiphong 5
Nanchang 5
Nürnberg 5
Belo Horizonte 4
Bologna 4
Catania 4
Changsha 4
Hebei 4
Johannesburg 4
Newark 4
Orem 4
Quanzhou 4
São Paulo 4
Warsaw 4
Athens 3
Brasília 3
Cattolica 3
Eitensheim 3
Evanston 3
Falciano 3
Florence 3
Hangzhou 3
Lissone 3
Manchester 3
Manila 3
Nairobi 3
San Diego 3
Silver Spring 3
Tashkent 3
Thái Nguyên 3
Tianjin 3
Totale 2.230
Salva come PNG Salva come JPEG
Nome #
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial 380
Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART 300
96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation 246
Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era 236
Predictive factors of therapeutic success of a HAART regimen including atazanavir with or without ritonavir in HIV-infected patients 228
Maraviroc : un inibitore del co-recettore CCR5 con un unico profilo di efficacia e tollerabilita’ in diversi scenari clinici dell'infezione da HIV-1 227
Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy : A postauthorization noninterventional study 221
Integrase inhibitors use and CMV infection predict immune recovery in peolple living with HIV starting first-line therapy 218
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 214
Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens 183
ACE inhibitors and ribavirin-associated cough: a common undefined predisposing factor? 182
Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial 178
Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients 169
The contribution of immune activation and accelerated aging in multiple myeloma occurring in HIV-infected population 169
Factors involved in continuance of atazanavir-based regimens : Results from a cohort of HIV1-positive patients 168
Treatment outcome in HIV+ patients receiving 3- or 4-drug regimens during PHI 157
Hepatitis C virus-related factors associated WITH cognitive performance in HIV-HCV-coinfected patients 143
Safety of Sofosbuvir-Based Direct-Acting Antivirals for Hepatitis C Virus Infection and Direct Oral Anticoagulant Co-Administration 116
null 6
Totale 3.741
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.206
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.206
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022239 26 11 5 4 4 15 14 27 39 32 11 51
2022/2023358 46 50 39 38 27 68 4 22 42 1 19 2
2023/2024192 7 21 15 27 33 21 3 11 5 11 16 22
2024/2025548 11 45 5 71 28 31 23 66 24 54 53 137
2025/20261.277 128 85 130 75 108 68 200 47 101 55 174 106
2026/202731 31 0 0 0 0 0 0 0 0 0 0 0
Totale 3.741